Evidence map›Paper›PMID 42349530›Full record

ArticleBone2026

Local delivery of rhBMP-2 affects systemic metabolic response during healing of critically-sized segmental defects in a rat model.

Elisabeth M Schwiebert, Lia K Strait, Samuel G Moore, David A Gaul, Facundo M Fernández, Robert E Guldberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elisabeth M SchwiebertSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332, United States.
Lia K StraitPhil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, 97403, United States.
Samuel G MoorePetit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, United States.
David A GaulSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332, United States; Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, United States.
Facundo M FernándezSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332, United States; Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, United States.
Robert E GuldbergPhil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, 97403, United States. Electronic address: guldberg@uoregon.edu.

Funding

Regenerative Rehabilitation of Complex Musculoskeletal InjuriesR01AR069297 · NIAMS · UNIVERSITY OF OREGON · 2024 to 2025
$1.2M
NIAMS NIH HHS R01 AR069297
6 · The paper itself

Abstract

Understanding the biological mechanisms behind fracture nonunions and their treatments remains incomplete. Since these mechanisms are linked to phenotypic expression, studying the longitudinal metabolic profile of bone regeneration has emerged as a potential way to better understand healing progress and treatment effectiveness. In this study, we tracked the serum metabolome of rats with critically-sized femoral defects treated with either a control, a minimum effective dose, or a supraphysiologic dose of rhBMP-2 over time. We observed distinct changes in the metabolome across control, impaired healing, and rhBMP-2-treated animals. Early in the process, we saw increased levels of metabolites that support angiogenesis in the rhBMP-2 groups. Supraphysiologic doses of rhBMP-2 significantly affected metabolite expression, especially in pathways related to angiogenesis, fatty acid metabolism, and ATP production. These longitudinal trends and individual metabolite changes provide a deeper understanding of rhBMP-2's mechanisms, improve our knowledge of its biological effects-guiding appropriate dosing-and offer a metabolic profile that may indicate healing impairment.

Indexed as

Bone Morphogenetic Protein 2Fracture HealingTransforming Growth Factor betaAnimalsDisease Models, AnimalFemurMaleMetabolomeRatsRats, Sprague-DawleyRecombinant ProteinsBone Morphogenetic Protein 2recombinant human bone morphogenetic protein-2Recombinant ProteinsTransforming Growth Factor betaBone healingMetabolomicsRecombinant human bone morphologic protein-2Ultrahigh performance liquid chromatography-mass spectrometry

Identifiers

PMID42349530
PMCPMC13356914

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.